Overview: Plasminogen Activator Inhibitor-1 TestIntroduction: The Plasminogen Activator Inhibitor-1 Test measures PAI-1 levels to diagnose clotting disorders, causing thrombosis or bleeding. Aligned with 2023 ISTH guidelines, it uses biochemical methods for high specificity, supporting coagulation screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected thrombophilia or bleeding disorders.
Other Names: PAI-1 Assay, Clotting Inhibitor Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: PAI-1 testing began in the 1980s with thrombosis research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures PAI-1 levels to diagnose clotting disorders, guides treatment, and evaluates patients with thrombosis or bleeding.
Test Parameters: 1. PAI-1 Level
Pretest Condition: Fasting for 10-12 hours required. Collect serum or plasma. Report history of thrombosis, bleeding, or clotting symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (NaCit, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document thrombosis, bleeding, or family history of clotting disorders. Include current medications, especially anticoagulants.
Consent: Written consent required, detailing the tests purpose, clotting disorder implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to measure PAI-1 levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for clotting disorder diagnosis.
Factors Affecting Result Accuracy: Improper fasting or sample hemolysis can affect results. Diurnal variation may impact PAI-1 levels.
Clinical Significance: Elevated PAI-1 confirms thrombophilia, guiding anticoagulant therapy. Low levels may indicate bleeding risk, requiring further evaluation.
Specialist Consultation: Consult a hematologist for result interpretation and treatment planning.
Additional Supporting Tests: D-dimer, fibrinogen, or genetic testing (e.g., PAI-1 4G/5G) to confirm clotting disorder diagnosis.
Test Limitations: Non-specific for certain clotting disorders; clinical correlation is needed. Sample quality affects sensitivity.
References: ISTH Thrombophilia Guidelines, 2023; Journal of Thrombosis and Haemostasis, Declerck PJ, 2022.
